CMPS Stock Climbs After-Hours: Analyst Sees Depression Drug Approval By H1 2027 Or Sooner After Strong Trial Data
The company’s rolling FDA application is underway, with final submission expected in Q4 and launch targeted for H1 2027.
Read the full articleYou might also wanna read
FDA Immunotherapy Approvals: First Half of 2026
FDA immunotherapy approvals in the first half of 2026 demonstrate the continued evolution of cancer immunotherapy beyond conventional checkp
FDA-Regulated AI Mood Tracking in Mental Health Apps
Building AI mood tracking in mental health apps in 2026? Learn what triggers FDA regulation, what stays wellness, and how to build compliant
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
July 10 (Reuters) - Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday. The b
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
July 10 (Reuters) - Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday. The b
FDA Issues Revised Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drugs and Biological Products
On June 22, 2026, the U.S. Department of Health and Human Services (HHS) unveiled Operation TrialBlazer, a department-wide effort to acceler
Part I: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting.
Comments
Sign in to join the conversation.
No comments yet. Be the first.